{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:05:41Z","timestamp":1785852341613,"version":"3.56.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1097\/01.mcg.0000156113.14974.f5","type":"journal-article","created":{"date-parts":[[2005,3,9]],"date-time":"2005-03-09T04:02:18Z","timestamp":1110340938000},"page":"S247-S250","source":"Crossref","is-referenced-by-count":16,"title":["Psychotherapeutics and Serotonin Agonists and Antagonists"],"prefix":"10.1097","volume":"39","author":[{"given":"Howard","family":"Mertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0016-5085(91)90215-7","article-title":"A controlled trial of psychological treatment of the irritable bowel syndrome.","volume":"100","author":"Guthrie","year":"1991","journal-title":"Gastroenterology"},{"key":"R2-11-20210305","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(84)92793-4","article-title":"Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome.","volume":"2","author":"Whorwell","year":"1984","journal-title":"Lancet"},{"key":"R3-11-20210305","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(83)90678-5","article-title":"Controlled study of psychotherapy in irritable bowel syndrome.","volume":"2","author":"Svedland","year":"1983","journal-title":"Lancet"},{"key":"R4-11-20210305","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0002-9270(00)00729-2","article-title":"The combination of medical treatment plus multicomponent behavior therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome.","volume":"95","author":"Heymann-Monnikes","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R5-11-20210305","first-page":"277","article-title":"Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials.","volume":"91","author":"Talley","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R6-11-20210305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5085(03)00669-3","article-title":"Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.","volume":"125","author":"Drossman","year":"2003","journal-title":"Gastroenterology"},{"key":"R7-11-20210305","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00002826-198312000-00002","article-title":"Antidepressants in chronic pain.","volume":"6","author":"Walsh","year":"1983","journal-title":"Clin Neuropharmacol"},{"key":"R8-11-20210305","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.37.4.589","article-title":"Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.","volume":"37","author":"Max","year":"1987","journal-title":"Neurology"},{"key":"R9-11-20210305","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/bmj.314.7083.763","article-title":"Antidepressants and chronic pain.","volume":"314","author":"McQuay","year":"1997","journal-title":"Br Med J"},{"key":"R10-11-20210305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3959(98)00031-1","article-title":"Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon.","volume":"76","author":"Su","year":"1998","journal-title":"Pain"},{"key":"R11-11-20210305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410130209","article-title":"Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system.","volume":"13","author":"Botney","year":"1983","journal-title":"Ann Neurol"},{"key":"R12-11-20210305","first-page":"G460","article-title":"Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.","volume":"275","author":"Gorelick","year":"1998","journal-title":"Am J Physiol"},{"key":"R13-11-20210305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0304-3959(94)00142-2","article-title":"The hypoalgesic effect of imipramine in different human experimental pain models.","volume":"60","author":"Poulson","year":"1995","journal-title":"Pain"},{"key":"R14-11-20210305","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.42.6.807","article-title":"Imipramine decreases oesophageal pain perception in human male volunteers.","volume":"42","author":"Peghini","year":"1998","journal-title":"Gut"},{"key":"R15-11-20210305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1572-0241.1998.00160.x","article-title":"Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia.","volume":"93","author":"Mertz","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R16-11-20210305","first-page":"9914","article-title":"Evolution of visceral sensitivity in patients with irritable bowel syndrome.","volume":"47","author":"Poitras","year":"2002","journal-title":"Dig Dis Sci"},{"key":"R17-11-20210305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01297051","article-title":"Effects of desipramine on irritable bowel syndrome compared with atropine and placebo.","volume":"32","author":"Greenbaum","year":"1987","journal-title":"Dig Dis Sci"},{"key":"R18-11-20210305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(99)00299-5","article-title":"Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.","volume":"108","author":"Jackson","year":"2000","journal-title":"Am J Med"},{"key":"R19-11-20210305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0447.1982.tb00912.x","article-title":"Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity.","volume":"66","author":"Lancaster-Smith","year":"1982","journal-title":"Acta Psychiatrica Scandanavia"},{"key":"R20-11-20210305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/gast.2003.50055","article-title":"The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.","volume":"124","author":"Creed","year":"2003","journal-title":"Gastroenterology"},{"key":"R21-11-20210305","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0016-5085(98)70203-3","article-title":"5-Hydroxytryptamine-4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.","volume":"115","author":"Grider","year":"1998","journal-title":"Gastroenterology"},{"key":"R22-11-20210305","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/gast.1996.v111.pm8898642","article-title":"Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine.","volume":"111","author":"Foxx-Orenstein","year":"1996","journal-title":"Gastroenterology"},{"key":"R23-11-20210305","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist accelerates gastric emptying and gastrointestinal transit in healthy male subjects.","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-11-20210305","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2004.03.013","article-title":"Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.","volume":"126","author":"Coates","year":"2004","journal-title":"Gastroenterology"},{"key":"R25-11-20210305","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","article-title":"Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and post-dysenteric irritable bowel syndrome.","volume":"47","author":"Spiller","year":"2000","journal-title":"Gut"},{"key":"R26-11-20210305","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist accelerates gastric emptying and gastrointestinal transit in healthy male subjects.","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-11-20210305","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"R28-11-20210305","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-11-20210305","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-11-20210305","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.","volume":"52","author":"Kellow","year":"2002","journal-title":"Gut"},{"key":"R31-11-20210305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/gast.2002.34245","article-title":"Expression of 5-HT3 receptors in the rat gastrointestinal tract.","volume":"123","author":"Glatzle","year":"2002","journal-title":"Gastroenterology"},{"key":"R32-11-20210305","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01536922","article-title":"GR38032F (ondansetron), a selective 5-HT3 receptor antagonist slows colonic transit in healthy men.","volume":"35","author":"Talley","year":"1990","journal-title":"Dig Dis Sci"},{"key":"R33-11-20210305","first-page":"G498","article-title":"Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex.","volume":"275","author":"Bjornsson","year":"1998","journal-title":"Am J Physiol"},{"key":"R34-11-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1365-2036.1999.00009.x","article-title":"Review article: clinical pharmacology of alosetron.","volume":"13","author":"Gunput","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-11-20210305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-11-20210305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1023\/A:1026633629141","article-title":"Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.","volume":"44","author":"Miura","year":"1999","journal-title":"Dig Dis Sci"},{"key":"R37-11-20210305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2036.1993.tb00087.x","article-title":"Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT antagonist in patients with irritable bowel syndrome.","volume":"7","author":"Prior","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-11-20210305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/gut.46.4.474","article-title":"The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized rat.","volume":"46","author":"Kozlowski","year":"2000","journal-title":"Gut"},{"key":"R39-11-20210305","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.","volume":"16","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"R40-11-20210305","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial.","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"R41-11-20210305","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1572-0241.2001.03525.x","article-title":"Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.","volume":"96","author":"Watson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R42-11-20210305","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.1999.00678.x","article-title":"Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.","volume":"13","author":"Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R43-11-20210305","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/gast.2001.21177","article-title":"Ischemic colitis during treatment with alosetron.","volume":"120","author":"Friedel","year":"2001","journal-title":"Gastroenterology"},{"key":"R46-11-20210305","first-page":"A42","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study.","volume":"126","author":"Bradette","year":"2004","journal-title":"Gastroenterology"},{"key":"R47-11-20210305","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome.","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"issue":"suppl 2","key":"R48-11-20210305","first-page":"1","article-title":"British society of gastroenterology guidelines for the management of the irritable bowel syndrome.","volume":"47","author":"Jones","year":"2000","journal-title":"Gut"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mcg.0000156113.14974.f5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:41:23Z","timestamp":1785850883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200505003-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mcg.0000156113.14974.f5","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}